Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab after salvage surgery for recurrent or persistent head and neck squamous cell carcinoma after radiotherapy
ChiCTR2200055723Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Disease-free survival. Started Oct 2021; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200055723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055723.